LEADER 01839nam  2200373   450 
001 9910688492603321
005 20230623121547.0
024 7 $a10.5772/intechopen.83098
035   $a(CKB)5400000000040660
035   $a(NjHacI)995400000000040660
035   $a(EXLCZ)995400000000040660
100   $a20230623d2020      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aAsbestos-related Diseases /$fedited by Takemi Otsuki
210  1$aLondon, England :$cIntechOpen,$d2020.
215   $a1 online resource (80 pages)
311   $a1-83880-834-5 
330   $aThe issue of asbestos exposure and the resulting health problems is now a global problem. The World Health Organization (WHO) has made recommendations on the eradication of asbestos-related diseases. However, malignant mesothelioma, mainly due to asbestos exposure, is a refractory malignant tumor, and technological innovation in diagnosis and treatment is required. In this context, this book describes the immunological effects of asbestos exposure, blood biomarkers, the pathology of malignant mesothelioma, and the status of immune checkpoint drugs in the treatment of malignant mesothelioma, along with the status of MMP mesothelioma. Concerns about health hazards associated with asbestos exposure may persist for many years to come. We hope this book will help researchers in this area.
606   $aAsbestos$xHealth aspects
606   $aAsbestos$xToxicology
615  0$aAsbestos$xHealth aspects.
615  0$aAsbestos$xToxicology.
676   $a363.1791
702   $aOtsuki$b Takemi
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688492603321
996   $aAsbestos-related Diseases$92211034
997   $aUNINA